Review



human pancreatic cancer cell lines hs766t  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC human pancreatic cancer cell lines hs766t
    Numbers of NOD/SCID mice tested for each cancer cell implant and for each treatment group.
    Human Pancreatic Cancer Cell Lines Hs766t, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 453 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pancreatic cancer cell lines hs766t/product/ATCC
    Average 96 stars, based on 453 article reviews
    human pancreatic cancer cell lines hs766t - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice"

    Article Title: Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

    Journal: Journal of cancer science & therapy

    doi: 10.4172/1948-5956.1000219

    Numbers of NOD/SCID mice tested for each cancer cell implant and for each treatment group.
    Figure Legend Snippet: Numbers of NOD/SCID mice tested for each cancer cell implant and for each treatment group.

    Techniques Used:

    NOD/SCID mice transplanted with Hs766t (n =27 total), MIA PaCa-2 (n =10 total) or MDA231 cells (n =16 total) were treated with saline, Serp-1, or neuroserpin for 2 weeks. Four weeks after transplantation, tumors excised from each group were weighed. (A) Growth of Hs766t xenografts was inhibited in mice receiving neuroserpin (n =6, P= 0.01) or Serp-1 (n =9, P= 0.03) treatment, when compared to saline (n =12). (B) Serp-1 treatment (n=5) also inhibited growth of another pancreatic cancer cell line, MIA PaCa-2 in NOD/SCID mice when compared to saline treatment (n =5, P ≤ 0.02). (C) Growth of the breast cancer cell isolate, MDA231 cells in NOD/SCID mice was not inhibited by neuroserpin (n=5, P= 0.76) or Serp-1 (n=6, P= 0.70). (D) In the time course study, NOD/SCID mice transplanted with Hs766t cells were treated each day with saline or Serp-1 throughout the 4 week experiment. Tumor suppressive effects of Serp-1 were evident after three weeks of treatment (P < 0.02). * indicates significance of P ≤ 0.05.
    Figure Legend Snippet: NOD/SCID mice transplanted with Hs766t (n =27 total), MIA PaCa-2 (n =10 total) or MDA231 cells (n =16 total) were treated with saline, Serp-1, or neuroserpin for 2 weeks. Four weeks after transplantation, tumors excised from each group were weighed. (A) Growth of Hs766t xenografts was inhibited in mice receiving neuroserpin (n =6, P= 0.01) or Serp-1 (n =9, P= 0.03) treatment, when compared to saline (n =12). (B) Serp-1 treatment (n=5) also inhibited growth of another pancreatic cancer cell line, MIA PaCa-2 in NOD/SCID mice when compared to saline treatment (n =5, P ≤ 0.02). (C) Growth of the breast cancer cell isolate, MDA231 cells in NOD/SCID mice was not inhibited by neuroserpin (n=5, P= 0.76) or Serp-1 (n=6, P= 0.70). (D) In the time course study, NOD/SCID mice transplanted with Hs766t cells were treated each day with saline or Serp-1 throughout the 4 week experiment. Tumor suppressive effects of Serp-1 were evident after three weeks of treatment (P < 0.02). * indicates significance of P ≤ 0.05.

    Techniques Used: Saline, Transplantation Assay

    NOD/SCID mice transplanted with Hs766t or MDA231 were treated with M-T7 for 2 weeks. 4 weeks after transplantation, tumors were weighed. No significant tumor-inhibiting activity by M-T7 was seen in (A) pancreatic cancer cell Hs766t transplanted mice (n=8, P = 0.20) or (B) breast cancer cell MDA231 transplanted mice (n=16, P= 0.24).
    Figure Legend Snippet: NOD/SCID mice transplanted with Hs766t or MDA231 were treated with M-T7 for 2 weeks. 4 weeks after transplantation, tumors were weighed. No significant tumor-inhibiting activity by M-T7 was seen in (A) pancreatic cancer cell Hs766t transplanted mice (n=8, P = 0.20) or (B) breast cancer cell MDA231 transplanted mice (n=16, P= 0.24).

    Techniques Used: Transplantation Assay, Activity Assay

    Anti-Ki67 antibody was used to stain for proliferating cells (brown) in the tumor tissues. Pancreatic cancer Hs766t cell proliferation was inhibited in Serp-1 and neuroserpin-treated mice. (A - Saline, B- NSP, C - Serp-1) Pancreatic cancer tissues isolated from NOD/SCID mice at 4 weeks follow up and stained for Ki67 (arrows point to representative dividing cells). (D) Bar graphs illustrate comparisons of mean ± SE for positively stained cell counts for Ki67 positive cells in pancreatic cancer sections. Ki67 positive cells in five randomly selected high power fields (HPFs) were counted for each tumor tissue. The averages of positive cell counts in each treatment group were compared using ANOVA (n=40 HPFs total, *: significant level of P< 0.05). Breast cancer cell proliferation was not inhibited in vivo by Serp-1 and NSP treatment. (E- Saline, F - NSP, G - Serp-1) Breast cancer with Ki67 staining (arrows point to representative dividing cells). (H) Bar graphs show comparison of Ki67 positive cells in breast cancer MD-231 cell implants after treatments (n=50 HPFs total). Magnification: 400X.
    Figure Legend Snippet: Anti-Ki67 antibody was used to stain for proliferating cells (brown) in the tumor tissues. Pancreatic cancer Hs766t cell proliferation was inhibited in Serp-1 and neuroserpin-treated mice. (A - Saline, B- NSP, C - Serp-1) Pancreatic cancer tissues isolated from NOD/SCID mice at 4 weeks follow up and stained for Ki67 (arrows point to representative dividing cells). (D) Bar graphs illustrate comparisons of mean ± SE for positively stained cell counts for Ki67 positive cells in pancreatic cancer sections. Ki67 positive cells in five randomly selected high power fields (HPFs) were counted for each tumor tissue. The averages of positive cell counts in each treatment group were compared using ANOVA (n=40 HPFs total, *: significant level of P< 0.05). Breast cancer cell proliferation was not inhibited in vivo by Serp-1 and NSP treatment. (E- Saline, F - NSP, G - Serp-1) Breast cancer with Ki67 staining (arrows point to representative dividing cells). (H) Bar graphs show comparison of Ki67 positive cells in breast cancer MD-231 cell implants after treatments (n=50 HPFs total). Magnification: 400X.

    Techniques Used: Staining, Saline, Isolation, In Vivo, Comparison

    Cultured Hs766t cells were treated with Serp-1 at different doses or saline. MTT assay was performed to assess cell number at 24, 48, 72 and 96 hours and the growth curves of these treatment groups were created. Cell proliferation in vitro for each group showed no significant difference at all time points assayed (n=3 in each time point each treatment group).
    Figure Legend Snippet: Cultured Hs766t cells were treated with Serp-1 at different doses or saline. MTT assay was performed to assess cell number at 24, 48, 72 and 96 hours and the growth curves of these treatment groups were created. Cell proliferation in vitro for each group showed no significant difference at all time points assayed (n=3 in each time point each treatment group).

    Techniques Used: Cell Culture, Saline, MTT Assay, In Vitro

    (A) CD3 staining of splenocytes from a C57BL6 mouse is provided as a positive control. (B) Lack of CD3 positive T cells is shown in the NOD/SCID mice used for cancer cell transplantation. (C) Representative dot plot illustrates the MDSC population in mice with pancreatic cancer after control treatment with saline. (D) Representative dot plot illustrating MDSC population positive for CD11b and Gr-1 markers for MDSC in mice with pancreatic cancer treated with Serp-1. (E) MDSCs were increased with pancreatic cancer growth (P=0.01) and significantly decreased after Serp-1 treatment in mice transplanted with Hs766t (n=9 total, P<0.001) or MIA PaCa-2 cells (n=8 total, P=0.016). (F) MDSC cell counts assayed by flow cytometry in splenocytes from SCID mice after MD-231 breast cancer growth were not significantly altered after Serp-1 treatment (n=13 total, P=0.41).
    Figure Legend Snippet: (A) CD3 staining of splenocytes from a C57BL6 mouse is provided as a positive control. (B) Lack of CD3 positive T cells is shown in the NOD/SCID mice used for cancer cell transplantation. (C) Representative dot plot illustrates the MDSC population in mice with pancreatic cancer after control treatment with saline. (D) Representative dot plot illustrating MDSC population positive for CD11b and Gr-1 markers for MDSC in mice with pancreatic cancer treated with Serp-1. (E) MDSCs were increased with pancreatic cancer growth (P=0.01) and significantly decreased after Serp-1 treatment in mice transplanted with Hs766t (n=9 total, P<0.001) or MIA PaCa-2 cells (n=8 total, P=0.016). (F) MDSC cell counts assayed by flow cytometry in splenocytes from SCID mice after MD-231 breast cancer growth were not significantly altered after Serp-1 treatment (n=13 total, P=0.41).

    Techniques Used: Staining, Positive Control, Transplantation Assay, Control, Saline, Flow Cytometry

    Augmentation of uPA activity through uPA injection antagonized Serp-1 inhibition of pancreatic cancer growth. Hs766t cells suspended in uPA were injected subcutaneously into NOD/SCID mice, which then received Serp-1 or saline treatment with the same dosage and duration as described for prior studies. Serp-1 treatment no longer significantly inhibited macrophage infiltration in tumors (A, P=0.24, n=20 HPFs per group) or decreased MDSCs in the spleens (B, P=0.20, n=4 per group). (C)Tumor growth in these mice was not suppressed by Serp-1 treatment (P=0.26, n=4 per group).
    Figure Legend Snippet: Augmentation of uPA activity through uPA injection antagonized Serp-1 inhibition of pancreatic cancer growth. Hs766t cells suspended in uPA were injected subcutaneously into NOD/SCID mice, which then received Serp-1 or saline treatment with the same dosage and duration as described for prior studies. Serp-1 treatment no longer significantly inhibited macrophage infiltration in tumors (A, P=0.24, n=20 HPFs per group) or decreased MDSCs in the spleens (B, P=0.20, n=4 per group). (C)Tumor growth in these mice was not suppressed by Serp-1 treatment (P=0.26, n=4 per group).

    Techniques Used: Activity Assay, Injection, Inhibition, Saline



    Similar Products

    human pancreatic cancer cell lines hs766t  (ATCC)
    96
    ATCC human pancreatic cancer cell lines hs766t
    Numbers of NOD/SCID mice tested for each cancer cell implant and for each treatment group.
    Human Pancreatic Cancer Cell Lines Hs766t, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pancreatic cancer cell lines hs766t/product/ATCC
    Average 96 stars, based on 1 article reviews
    human pancreatic cancer cell lines hs766t - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    hs766t human pancreatic cancer cell lines  (ATCC)
    96
    ATCC hs766t human pancreatic cancer cell lines
    Numbers of NOD/SCID mice tested for each cancer cell implant and for each treatment group.
    Hs766t Human Pancreatic Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hs766t human pancreatic cancer cell lines/product/ATCC
    Average 96 stars, based on 1 article reviews
    hs766t human pancreatic cancer cell lines - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Numbers of NOD/SCID mice tested for each cancer cell implant and for each treatment group.

    Journal: Journal of cancer science & therapy

    Article Title: Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

    doi: 10.4172/1948-5956.1000219

    Figure Lengend Snippet: Numbers of NOD/SCID mice tested for each cancer cell implant and for each treatment group.

    Article Snippet: Human pancreatic cancer cell lines Hs766t (ATCC HTB-134) and MIA PaCa-2 (ATCC CRL-1420), human breast cancer cell line MDA231 (ATCC HTB-26), human acute myelogenous leukemia cell line KG-1 (ATCC CCL-246), and human hepatocarcinoma cell line Huh7.5 were cultured in monolayer with DMEM supplemented with 10% fetal bovine serum (FBS).

    Techniques:

    NOD/SCID mice transplanted with Hs766t (n =27 total), MIA PaCa-2 (n =10 total) or MDA231 cells (n =16 total) were treated with saline, Serp-1, or neuroserpin for 2 weeks. Four weeks after transplantation, tumors excised from each group were weighed. (A) Growth of Hs766t xenografts was inhibited in mice receiving neuroserpin (n =6, P= 0.01) or Serp-1 (n =9, P= 0.03) treatment, when compared to saline (n =12). (B) Serp-1 treatment (n=5) also inhibited growth of another pancreatic cancer cell line, MIA PaCa-2 in NOD/SCID mice when compared to saline treatment (n =5, P ≤ 0.02). (C) Growth of the breast cancer cell isolate, MDA231 cells in NOD/SCID mice was not inhibited by neuroserpin (n=5, P= 0.76) or Serp-1 (n=6, P= 0.70). (D) In the time course study, NOD/SCID mice transplanted with Hs766t cells were treated each day with saline or Serp-1 throughout the 4 week experiment. Tumor suppressive effects of Serp-1 were evident after three weeks of treatment (P < 0.02). * indicates significance of P ≤ 0.05.

    Journal: Journal of cancer science & therapy

    Article Title: Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

    doi: 10.4172/1948-5956.1000219

    Figure Lengend Snippet: NOD/SCID mice transplanted with Hs766t (n =27 total), MIA PaCa-2 (n =10 total) or MDA231 cells (n =16 total) were treated with saline, Serp-1, or neuroserpin for 2 weeks. Four weeks after transplantation, tumors excised from each group were weighed. (A) Growth of Hs766t xenografts was inhibited in mice receiving neuroserpin (n =6, P= 0.01) or Serp-1 (n =9, P= 0.03) treatment, when compared to saline (n =12). (B) Serp-1 treatment (n=5) also inhibited growth of another pancreatic cancer cell line, MIA PaCa-2 in NOD/SCID mice when compared to saline treatment (n =5, P ≤ 0.02). (C) Growth of the breast cancer cell isolate, MDA231 cells in NOD/SCID mice was not inhibited by neuroserpin (n=5, P= 0.76) or Serp-1 (n=6, P= 0.70). (D) In the time course study, NOD/SCID mice transplanted with Hs766t cells were treated each day with saline or Serp-1 throughout the 4 week experiment. Tumor suppressive effects of Serp-1 were evident after three weeks of treatment (P < 0.02). * indicates significance of P ≤ 0.05.

    Article Snippet: Human pancreatic cancer cell lines Hs766t (ATCC HTB-134) and MIA PaCa-2 (ATCC CRL-1420), human breast cancer cell line MDA231 (ATCC HTB-26), human acute myelogenous leukemia cell line KG-1 (ATCC CCL-246), and human hepatocarcinoma cell line Huh7.5 were cultured in monolayer with DMEM supplemented with 10% fetal bovine serum (FBS).

    Techniques: Saline, Transplantation Assay

    NOD/SCID mice transplanted with Hs766t or MDA231 were treated with M-T7 for 2 weeks. 4 weeks after transplantation, tumors were weighed. No significant tumor-inhibiting activity by M-T7 was seen in (A) pancreatic cancer cell Hs766t transplanted mice (n=8, P = 0.20) or (B) breast cancer cell MDA231 transplanted mice (n=16, P= 0.24).

    Journal: Journal of cancer science & therapy

    Article Title: Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

    doi: 10.4172/1948-5956.1000219

    Figure Lengend Snippet: NOD/SCID mice transplanted with Hs766t or MDA231 were treated with M-T7 for 2 weeks. 4 weeks after transplantation, tumors were weighed. No significant tumor-inhibiting activity by M-T7 was seen in (A) pancreatic cancer cell Hs766t transplanted mice (n=8, P = 0.20) or (B) breast cancer cell MDA231 transplanted mice (n=16, P= 0.24).

    Article Snippet: Human pancreatic cancer cell lines Hs766t (ATCC HTB-134) and MIA PaCa-2 (ATCC CRL-1420), human breast cancer cell line MDA231 (ATCC HTB-26), human acute myelogenous leukemia cell line KG-1 (ATCC CCL-246), and human hepatocarcinoma cell line Huh7.5 were cultured in monolayer with DMEM supplemented with 10% fetal bovine serum (FBS).

    Techniques: Transplantation Assay, Activity Assay

    Anti-Ki67 antibody was used to stain for proliferating cells (brown) in the tumor tissues. Pancreatic cancer Hs766t cell proliferation was inhibited in Serp-1 and neuroserpin-treated mice. (A - Saline, B- NSP, C - Serp-1) Pancreatic cancer tissues isolated from NOD/SCID mice at 4 weeks follow up and stained for Ki67 (arrows point to representative dividing cells). (D) Bar graphs illustrate comparisons of mean ± SE for positively stained cell counts for Ki67 positive cells in pancreatic cancer sections. Ki67 positive cells in five randomly selected high power fields (HPFs) were counted for each tumor tissue. The averages of positive cell counts in each treatment group were compared using ANOVA (n=40 HPFs total, *: significant level of P< 0.05). Breast cancer cell proliferation was not inhibited in vivo by Serp-1 and NSP treatment. (E- Saline, F - NSP, G - Serp-1) Breast cancer with Ki67 staining (arrows point to representative dividing cells). (H) Bar graphs show comparison of Ki67 positive cells in breast cancer MD-231 cell implants after treatments (n=50 HPFs total). Magnification: 400X.

    Journal: Journal of cancer science & therapy

    Article Title: Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

    doi: 10.4172/1948-5956.1000219

    Figure Lengend Snippet: Anti-Ki67 antibody was used to stain for proliferating cells (brown) in the tumor tissues. Pancreatic cancer Hs766t cell proliferation was inhibited in Serp-1 and neuroserpin-treated mice. (A - Saline, B- NSP, C - Serp-1) Pancreatic cancer tissues isolated from NOD/SCID mice at 4 weeks follow up and stained for Ki67 (arrows point to representative dividing cells). (D) Bar graphs illustrate comparisons of mean ± SE for positively stained cell counts for Ki67 positive cells in pancreatic cancer sections. Ki67 positive cells in five randomly selected high power fields (HPFs) were counted for each tumor tissue. The averages of positive cell counts in each treatment group were compared using ANOVA (n=40 HPFs total, *: significant level of P< 0.05). Breast cancer cell proliferation was not inhibited in vivo by Serp-1 and NSP treatment. (E- Saline, F - NSP, G - Serp-1) Breast cancer with Ki67 staining (arrows point to representative dividing cells). (H) Bar graphs show comparison of Ki67 positive cells in breast cancer MD-231 cell implants after treatments (n=50 HPFs total). Magnification: 400X.

    Article Snippet: Human pancreatic cancer cell lines Hs766t (ATCC HTB-134) and MIA PaCa-2 (ATCC CRL-1420), human breast cancer cell line MDA231 (ATCC HTB-26), human acute myelogenous leukemia cell line KG-1 (ATCC CCL-246), and human hepatocarcinoma cell line Huh7.5 were cultured in monolayer with DMEM supplemented with 10% fetal bovine serum (FBS).

    Techniques: Staining, Saline, Isolation, In Vivo, Comparison

    Cultured Hs766t cells were treated with Serp-1 at different doses or saline. MTT assay was performed to assess cell number at 24, 48, 72 and 96 hours and the growth curves of these treatment groups were created. Cell proliferation in vitro for each group showed no significant difference at all time points assayed (n=3 in each time point each treatment group).

    Journal: Journal of cancer science & therapy

    Article Title: Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

    doi: 10.4172/1948-5956.1000219

    Figure Lengend Snippet: Cultured Hs766t cells were treated with Serp-1 at different doses or saline. MTT assay was performed to assess cell number at 24, 48, 72 and 96 hours and the growth curves of these treatment groups were created. Cell proliferation in vitro for each group showed no significant difference at all time points assayed (n=3 in each time point each treatment group).

    Article Snippet: Human pancreatic cancer cell lines Hs766t (ATCC HTB-134) and MIA PaCa-2 (ATCC CRL-1420), human breast cancer cell line MDA231 (ATCC HTB-26), human acute myelogenous leukemia cell line KG-1 (ATCC CCL-246), and human hepatocarcinoma cell line Huh7.5 were cultured in monolayer with DMEM supplemented with 10% fetal bovine serum (FBS).

    Techniques: Cell Culture, Saline, MTT Assay, In Vitro

    (A) CD3 staining of splenocytes from a C57BL6 mouse is provided as a positive control. (B) Lack of CD3 positive T cells is shown in the NOD/SCID mice used for cancer cell transplantation. (C) Representative dot plot illustrates the MDSC population in mice with pancreatic cancer after control treatment with saline. (D) Representative dot plot illustrating MDSC population positive for CD11b and Gr-1 markers for MDSC in mice with pancreatic cancer treated with Serp-1. (E) MDSCs were increased with pancreatic cancer growth (P=0.01) and significantly decreased after Serp-1 treatment in mice transplanted with Hs766t (n=9 total, P<0.001) or MIA PaCa-2 cells (n=8 total, P=0.016). (F) MDSC cell counts assayed by flow cytometry in splenocytes from SCID mice after MD-231 breast cancer growth were not significantly altered after Serp-1 treatment (n=13 total, P=0.41).

    Journal: Journal of cancer science & therapy

    Article Title: Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

    doi: 10.4172/1948-5956.1000219

    Figure Lengend Snippet: (A) CD3 staining of splenocytes from a C57BL6 mouse is provided as a positive control. (B) Lack of CD3 positive T cells is shown in the NOD/SCID mice used for cancer cell transplantation. (C) Representative dot plot illustrates the MDSC population in mice with pancreatic cancer after control treatment with saline. (D) Representative dot plot illustrating MDSC population positive for CD11b and Gr-1 markers for MDSC in mice with pancreatic cancer treated with Serp-1. (E) MDSCs were increased with pancreatic cancer growth (P=0.01) and significantly decreased after Serp-1 treatment in mice transplanted with Hs766t (n=9 total, P<0.001) or MIA PaCa-2 cells (n=8 total, P=0.016). (F) MDSC cell counts assayed by flow cytometry in splenocytes from SCID mice after MD-231 breast cancer growth were not significantly altered after Serp-1 treatment (n=13 total, P=0.41).

    Article Snippet: Human pancreatic cancer cell lines Hs766t (ATCC HTB-134) and MIA PaCa-2 (ATCC CRL-1420), human breast cancer cell line MDA231 (ATCC HTB-26), human acute myelogenous leukemia cell line KG-1 (ATCC CCL-246), and human hepatocarcinoma cell line Huh7.5 were cultured in monolayer with DMEM supplemented with 10% fetal bovine serum (FBS).

    Techniques: Staining, Positive Control, Transplantation Assay, Control, Saline, Flow Cytometry

    Augmentation of uPA activity through uPA injection antagonized Serp-1 inhibition of pancreatic cancer growth. Hs766t cells suspended in uPA were injected subcutaneously into NOD/SCID mice, which then received Serp-1 or saline treatment with the same dosage and duration as described for prior studies. Serp-1 treatment no longer significantly inhibited macrophage infiltration in tumors (A, P=0.24, n=20 HPFs per group) or decreased MDSCs in the spleens (B, P=0.20, n=4 per group). (C)Tumor growth in these mice was not suppressed by Serp-1 treatment (P=0.26, n=4 per group).

    Journal: Journal of cancer science & therapy

    Article Title: Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

    doi: 10.4172/1948-5956.1000219

    Figure Lengend Snippet: Augmentation of uPA activity through uPA injection antagonized Serp-1 inhibition of pancreatic cancer growth. Hs766t cells suspended in uPA were injected subcutaneously into NOD/SCID mice, which then received Serp-1 or saline treatment with the same dosage and duration as described for prior studies. Serp-1 treatment no longer significantly inhibited macrophage infiltration in tumors (A, P=0.24, n=20 HPFs per group) or decreased MDSCs in the spleens (B, P=0.20, n=4 per group). (C)Tumor growth in these mice was not suppressed by Serp-1 treatment (P=0.26, n=4 per group).

    Article Snippet: Human pancreatic cancer cell lines Hs766t (ATCC HTB-134) and MIA PaCa-2 (ATCC CRL-1420), human breast cancer cell line MDA231 (ATCC HTB-26), human acute myelogenous leukemia cell line KG-1 (ATCC CCL-246), and human hepatocarcinoma cell line Huh7.5 were cultured in monolayer with DMEM supplemented with 10% fetal bovine serum (FBS).

    Techniques: Activity Assay, Injection, Inhibition, Saline